PARIS – Pooled analysis of phase 3 trials spotlights one clinical setting where brodalumab is particularly advantageous.
PARIS – More than 90% of PASI 75 responders to tildrakizumab at 6 months maintained at least a PASI 75 response at 148 weeks.
Psoriasis is associated with cardiovascular risk factors and myocardial infarction, but regular physical activity is known to decrease the risk of...
PARIS – Results of the first-ever randomized trial of biologic dose reduction in well-controlled psoriasis patients are reported.
Psoriasis Treatment in HIV-Positive Patients: A Systematic Review of Systemic Immunosuppressive Therapies
The management of psoriatic disease in the human immunodeficiency virus (HIV)–positive population is challenging...
From the Journals
The tool performed suboptimally overall, but had good sensitivity and specificity in patients with active symptoms.
Lilly described top-line results for the SPIRIT-H2H trial.
Peer to Peer
In this edition of the "Peer to Peer" audiocast series, Dr. Vincent DeLeo speaks with Dr. George Han about the dermatologist's role in treating...
CHICAGO – Translational study brings a genetic test for psoriatic arthritis one step closer.